Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy

Abstract Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Tafamidis demonstrated efficacy in ATTR-CM clinical trials; however, real-world disease outcomes are not thoroughly characterized. We examined real-world outcomes among patients with wild-type...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daniel P. Judge, Margarita Udall, Andrew M. Rosen, Neil Lamarre, Elizabeth Nagelhout, Hanh Dung Dao, Mathew S. Maurer
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-12-01
Colecção:	Cardiology and Therapy
Assuntos:	ATTR-CM Cardiovascular hospitalization Heart failure NT-proBNP Real-world evidence Tafamidis
Acesso em linha:	https://doi.org/10.1007/s40119-025-00443-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!